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Objectives: In Korea, a large portion of tuberculosis (TB) patients are diagnosed
and treated in private institutes. Laboratory tests are crucial for TB control.
There are many possible problems using laboratory tests in the private sector. In
this study, we aimed to investigate the characteristics and trends of utilizing
laboratory tests for TB and mycobacterial diseases in the private sector by
analyzing the National Health Insurance (NHI) database.
Methods: After selecting TB or other mycobacteria-related test items, we
searched the number and cost of each item on the website of the Health Insurance
Review and Assessment Service using the code of each test from 2007 to 2012.
Results: Our data revealed that the number and cost of tests drastically increased
between 2007 and 2012. Culture and molecular tests primarily contributed to the
tremendous increases. For each year, concentrated smearing and fluorochrome
staining were more commonly used. The number of serologic tests for latent TB
infection stagnated, despite the expansion of contact investigation.
Conclusion: The NHI data could be considerably useful for understanding the
utilization trends of laboratory tests for TB and mycobacterial diseases in Korea.
Our data showed that TB laboratory systems have recently improved. In this study,
many issues were noticed. Therefore, solutions to these issues are required and
the continued monitoring of NHI data regarding laboratory diagnosis.1. Introduction
Tuberculosis (TB) is a very serious health threat in the
world [1]. Many people develop and die of TB. Diag-
nosis and treatment are important pillars for controlling
and eradicating TB, and laboratory tests are crucial for itsted under the terms of the
) which permits unrestrict
operly cited.
ase Control and Preventiondiagnosis. The roles of TB laboratory tests are to detect
patients with TB, determine drug susceptibility, and
monitor treatment response. Several conventional tests
have been used for almost a century. However, there
have been tremendous changes in TB diagnosis, and
many new diagnostics have been introduced andCreative Commons Attribution Non-Commercial License (http://
ed non-commercial use, distribution, and reproduction in any
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use of various laboratory tests is necessary. The World
Health Organization (WHO) released guidelines or pol-
icy statements regarding diagnosis to help TB programs
use laboratory tests properly and adopt optimal diag-
nostic processes. Many countries, including Korea, pre-
pare their own national guidelines for diagnosis and
enable health workers to follow these guidelines [3].
However, this approach usually works well only in the
public sector, not the private sector. There are many
problems in the private sector in following a standardized
practice. According to a TB notification report from the
Korea Centers for Disease Control and Prevention
(KCDC), >90% of patients with TB went to private in-
stitutes [4]. There are presumably many problems in
using TB tests in the private sector, but few problems
have been revealed. South Korea has a National Health
Insurance (NHI) system, which is required by Korean
law. It manages all medical practices and every private
institute claims the fee of medical practice from NHI
system. In this study, we aimed to investigate the char-
acteristics and trends in the utilization of laboratory tests
for TB and mycobacterial diseases in the private sector
by analyzing the NHI database.2. Materials and methods
We analyzed the insurance data of laboratory tests in
relation to TB and mycobacterial diseases from 2007 to
2012. The names and insurance codes of the tests were
selected from the health insurance database. These areTable 1. Insurance codes and tested number of laboratory tests
Codes Name of test 2007
B4105 Direct AFB smear (fuschin staining) 269,314
B4021 Direct AFB smear (fluorochrome staining) 164,399
B4120 Concentrated AFB smear (fuschin staining) 417,516
BX304 Concentrated AFB smear
(fluorochrome staining)
240,335
B4054 Culture with solid media 641,642
B4055 Culture with liquid media 0
B4063 Drug susceptibility testing (<10 drugs) 1,773
B4064 Drug susceptibility testing (10 drugs) 24,557
C5953 TB PCR 19,549
CY051 TB nested PCR 36,347
C6021 TB real-time PCR 84,141
CY636 NTM identification 4,393
CY751 Rapid DST for RIF 1,565
CY752 Rapid DST for INH 1,088
CZ393 Interferon-gamma release assay 0
E7113 Tuberculin skin test 34,467
Total 1,941,086
AFB Z acid-fast bacilli; DST Z drug susceptibility testing; INH Z isonia
reaction; RIF Z rifampicin; TB Z tuberculosis.listed in Table 1 and included smear microscopy, cul-
ture, drug susceptibility testing (DST), nucleic acid
amplification test (NAAT), rapid DST, identification of
nontuberculous mycobacteria (NTM), and serologic
tests for latent TB infection. We searched utilization
information and the number of tests and their cost on the
website of the Health Insurance Review and Assessment
Service by using the code of each test (http://hira.or.kr/
rdd_disease.do?methodZlistInfoMdfee&pgmidZHIR
AA020044020200).3. Results
The total number of tests performed in 2007 was
1,941,086, which increased to 3,083,491 in 2012 (Table 1;
Figure 1). The cost for TB and NTM laboratory tests was
approximately 200million Korean won, but it increased to
more than twice this amount in 2012 (Figure 2).
3.1. Conventional tests
3.1.1. Smear microscopy
Smear microscopy was the most frequently used test
item for TB and NTM disease. In 2007, smear micro-
scopy accounted for 56.2% of all tests. Since then, the
proportion gradually declined and culture examination
exceeded smear microscopy. Although the tested num-
ber was very large, its cost accounted for 13% in 2012.
Smear microscopy had four types of smear preparation
and straining methods. The proportion of concentrated
smear tests with fuschin staining was highest in 2007;
thereafter, it gradually decreased. In 2012, concentratedfor TB and mycobacterial disease (2007e2012).
Year
2008 2009 2010 2011 2012
255,528 236,662 200,053 196,853 187,319
211,119 225,209 233,912 224,115 204,167
377,849 324,239 295,900 292,509 263,596
292,028 375,930 456,174 525,890 631,729
684,430 673,820 747,309 785,001 844,677
15,736 231,529 354,104 464,564 558,094
1,548 1,260 1,214 1,395 1,427
25,916 28,029 30,240 32,894 38,560
23,606 19,344 17,567 15,859 20,871
33,567 28,918 29,485 23,636 34,555
116,726 146,866 185,575 227,122 239,335
6,645 9,508 8,487 9,116 6,190
2,294 3,089 3,763 5,111 6,673
1,788 2,681 3,471 4,950 6,465
0 5,468 5,335 4,846 6,803
32,395 33,132 32,260 34,479 33,030
2,081,175 2,345,684 2,604,849 2,848,340 3,083,491
zid; NTM Z nontuberculous mycobacteria; PCR Z polymerase chain
Figure 1. Requested number of laboratory tests for tuberculosis and mycobacterial diseases for 2007e2012. The total number of
tests increased gradually in this period. Smear microscopy and culture examinations have the greatest number of tests. DSTZ drug
susceptibility testing; LTBIZ latent tuberculosis infection; NAATZ nucleic acid amplification test; NTM IDZ nontuberculous
mycobacteria identification.
Figure 2. The cost of laboratory tests for tuberculosis and mycobacterial diseases during 2007e2012. The total cost for labo-
ratory tests rapidly increased during this period. This increase is primarily because of increased utilization of NAAT and culture
examination. Smear is the most frequently requested test, but the proportion of smear microscopy is relatively low in cost.
DST Z drug susceptibility testing; LTBI Z latent tuberculosis infection; NAAT Z nucleic acid amplification test; NTM
ID Z nontuberculous mycobacteria identification.
S26 C.-K. Kim, et al
Laboratory tests for TB and mycobacterial disease S27smear with fluorochrome staining was the most
frequently performed test.
3.1.2. Culture examination
There are two test codes for culture examination
based on media type. The number of solid cultures
gradually increased during 2007e2012. Liquid culture
has been covered by health insurance since 2008, before
which only 15,736 liquid cultures were tested. However,
the number of liquid cultures thereafter rapidly
increased. In 2012, solid cultures and liquid cultures
were tested for 844,729 samples and 558,094 samples,
respectively. In 2012, culture examinations accounted
for 47.7% of all costs. Therefore, culture examination
ranked first in number and in cost in 2012.
3.1.3. DST
The number of drug susceptibility tests (DSTs)
increased gradually during 2007e2012. There are two
codes for DST based on the number of drugs tested.
However, in 2012, DST (for <10 drugs) was not
commonly used and its proportion was only 3.6%
(1,427/39,987 tests). During 2007e2012, there was no
increasing or decreasing trend in the use of DST (for




The number of TB NAATs dramatically increased
during 2007e2014. A total of 140,037 NAATs were
performed in 2007, but the tested number more than
doubled to 294,761 tests in 2012. The cost for NAAT
was 15,111,149 Korean won, which was the second
highest cost in 2012. Three methods were used for TB
NAAT in Korea: TB polymerase chain reaction (PCR),
TB nested PCR, and TB real-time PCR. TB PCR was
the most simple test and not widely used. TB nested
PCR was more commonly used, compared to TB PCR,
but the number of tests stagnated during 2007e2012.
TB real-time PCR was the most commonly used TB
NAAT.
3.2.2. Rapid DST
Rapid DST was available for rifampicin (RIF) and
isoniazid in Korea. Rapid DST was performed for only
26,330 samples in 2007 and for 13,138 samples in 2012.
The number of RIF and isoniazid tests were very
similar, which indicates that most laboratories tested
two drugs at the same time.
3.2.3. NTM identification
NTM identification tests numbered more than 9000
tests in 2009. The number of NTM identification tests
during 2010e2011 stagnated without any significant
change. However, in 2012, it suddenly declined to 6190
tests.3.3. Serologic tests for latent TB infection
3.3.1. Tuberculin skin test
A total of 34,467 tuberculin skin tests (TSTs) were
performed in 2007. Since then, the number of TSTs
stagnated. The proportion of TST was very small in
number and in cost.
3.3.2. Interferon-gamma release assay
The NHI system started covering interferon-gamma
release assay (IGRA) in 2009. Therefore, 3 years of data
were analyzed. In the 1st year, 5468 IGRAs were per-
formed. There was no significant change or increasing
trend in the utilization of IGRA during the first 3 years.
However, the number of IGRAs performed in 2012
increased to 6803 tests.4. Discussion
Standardized diagnosis and treatment are important
for successful TB control. Therefore, the KCDC pub-
lished Korean guidelines for TB in 2011, which was
intended to help physicians follow the standards. The
guidelines confirmed that physicians should use labo-
ratory tests for diagnosis of TB with chest x-ray [3]. The
recommendations of the guidelines include performing
cultures for every sample requested, using liquid cul-
tures along with solid media, and determining drug
susceptibility for all culture-positive TB patients and
rapid DST for multidrug-resistant TB (MDR-TB) sus-
pects [3]. These recommendations are very important
for the diagnosis and detection of drug-resistant TB.
Our results showed many problems in using labora-
tory tests. Essential tests were often neglected. In 2007,
more than one million smear examinations were per-
formed, but only 58.8% of them were cultured. The
number of RIF rapid DSTs performed in 2007 was 1565
tests, which was only 6.0% of DST.
Liquid culture has many advantages over solid cul-
ture [5]. It detects more TB cases in a shorter period of
time. Therefore, the WHO approves liquid culture as the
standard culture method [6]. However, liquid culture
had not been widely used in Korea because the insur-
ance fee for this culture is too low for laboratories to
perform liquid culture and there is no specific insurance
code for liquid culture. However, much improvement
occurred during 2007e2012. First, the proportion of
concentrated smear and fluorochrome staining
increased. In 2007, smear examination using concen-
tration accounted for 60% of all smears. The proportion
of smears using the concentration method increased to
69.6% in 2012. The proportion of fluorochrome staining
dramatically increased from 37.1% to 65.0% during that
period. According to Korean guidelines for TB, every
sample for which TB testing is requested should be
cultured using both liquid media and solid media. As
previously described, liquid culture has seldom been
S28 C.-K. Kim, et alused. In 2008, when liquid culture was approved by
NHI, only 15,736 samples were cultured with liquid
media. However, the number of liquid cultures rapidly
increased since then. In 2012, more than half a million
liquid cultures were performed, which is approximately
two-thirds of the number of solid cultures. Most samples
presumably will soon be cultured using both types of
media. Rapid DST is necessary for the timely detection
of MDR-TB [3,7]. Therefore, MDR-TB suspects who
should undergo rapid DST include MDR contacts, pa-
tients with a previous TB treatment history, and patients
with treatment failure. Initially, rapid DST was per-
formed for a few TB patients. However, the number of
rapid DSTs performed increased by more than four
times from 2007 to 2012. Xpert MTB/RIF (Xpert,
Cepheid, Sunnyvale, CA) was not included for analysis
because Xpert was not approved by the KCDC until
2013. The introduction of Xpert will influence the uti-
lization of rapid DST. Therefore, careful monitoring
must be followed.
There were other interesting findings from our anal-
ysis. Guidelines recommend determining the suscepti-
bility to first-line drugs for new TB cases and performing
DST of second-line drugs for TB cases resistant to first-
line drugs [3,7e9]. However, most DST was performed
for more than 10 drugs, and most TB cases seem to be
tested by DST of first- and second-line drugs simulta-
neously. This may be because testing a few drugs is less
profitable to a laboratory. The insurance fee for DST (for
<10 drugs) is unreasonably low, considering the expense
of the equipment, facility, human resources, and re-
agents. The number of DSTs had been gradually
increasing, but drastic increase was noticed in 2012. The
DST code actually covers both anti-TB testing and NTM
testing. NTM diseases are increasingly diagnosed and
more tests for NTM are being conducted in Korea. We
assumed that NTM DST may contribute to the rapid
increase in the number of drug susceptibility tests.
However, NTM identification was performed less in
2012 than in previous years, despite an increase in the
incidence of NTM disease. The insurance code (CY636)
for NTM identification specifically indicates the PCR-
restriction enzyme analysis method. Line probe assay
has been used more commonly for NTM identification
compared to the PCR-restriction enzyme analysis
method. Laboratories may use the code (C6021) for PCR
hybridization (i.e., real-time PCR), which is similar to the
line probe assay because there is no specific insurance
code for NTM identification using other methods. Even
though the KCDC has been trying hard to expand contact
investigation, the number of TSTs and IGRAs stagnated
between 2007 and 2012. It was partially because of this
that physicians were passive or reluctant to investigate
contacts. Most investigations are also conducted by the
central or local government.
The total number and cost of laboratory tests dras-
tically increased from 2007 to 2012. However, therehad been no significant change in TB notification
during the same period. It is difficult to explain what
influenced the trend in test utilization in the private
sector. We nonetheless assumed that the causes could
be expanded coverage of new diagnostics, improved
physician awareness, introduction of standardized
TB guidelines, and increased prevalence of NTM
diseases.
This study has several limitations. Institutes may
claim some tests by using the wrong insurance codes.
Some insurance codes can be used for different tests.
In that situation, it is impossible to collect information
about every test through the NHI data. Furthermore,
the NHI system officially specifies nonpayment ser-
vices and allows the patient to cover all their costs.
The NHI system has no record of these services;
therefore, this study was unable to include nonpayment
tests.
In conclusion, the NHI data would be very useful for
understanding trends in the utilization of laboratory tests
for TB and mycobacterial diseases in Korea. Our data
showed that TB laboratory systems have improved
recently. In this study, many issues were also noticed.
Therefore, solutions to these issues need to be found and
monitoring of NHI data concerning laboratory diagnosis
needs to continue.Conflicts of interest
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